Puja Kumari’s Post

Why Are Some IL-23 Biologics More Effective for Psoriasis? Dive into the molecular mechanisms behind IL-23 biologics and discover what sets certain treatments apart in managing moderate to severe psoriasis. This new article from the Journal of Drugs in Dermatology breaks down key structural insights that could impact your clinical decisions. Stay ahead in the evolving world of biologics and optimize care for your patients. Read the full article now: 🔗 https://lnkd.in/eQWtdSAi #Dermatology #Psoriasis #Biologics #IL23 #ClinicalDerm #JDD #MedicalResearch

📢 New Publication: “Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis” recently published in Journal of Drugs in Dermatology (JDD). In this article, we summarize a work that explores the structural properties of IL-23 biologics and their correlation with clinical efficacy in treating moderate and severe plaque psoriasis. Key factors examined include epitope surface area, binding affinity, and dissociation rates, which help explain why some biologics outperform others. Key findings: Risankizumab has the largest epitope surface area, stronger binding affinity and higher PASI-90 response rates compared to other IL-23 inhibitors. Clinical Implications: 1- Drug selection: These insights may assist clinicians in choosing biologics for patients who require robust efficacy and less frequent dosing. 2- Biologic switching: For patients not responding to one IL-23 inhibitor, switching to another, such as risankizumab, might still be effective due to distinct molecular characteristics. The study contributes to a deeper understanding of IL-23 biologics and their role in optimizing psoriasis treatment strategies. #Psoriasis #Dermatology #IL23 #Biologics #Research #Insights

Why Are Some IL-23 Biologics More Effective for Psoriasis? Dive into the molecular mechanisms behind IL-23 biologics and discover what sets certain treatments apart in managing moderate to severe psoriasis. This new article from the Journal of Drugs in Dermatology breaks down key structural insights that could impact your clinical decisions. Stay ahead in the evolving world of biologics and optimize care for your patients. Read the full article now: 🔗 https://lnkd.in/eD_wSsbw #Dermatology #Psoriasis #Biologics #IL23 #ClinicalDerm #JDD #MedicalResearch

🩺💡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐧𝐠 𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐩𝐡𝐲𝐭𝐢𝐜 𝐎𝐧𝐲𝐜𝐡𝐨𝐦𝐲𝐜𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 💅🌱 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gGvRhPpz 🌟 Key Highlights: Prevalent Fungal Infection: Dermatophytic onychomycosis is a common fungal infection affecting the nails, characterized by nail discoloration, thickening, and brittleness. Therapeutic Innovation: The market witnesses a surge in therapeutic innovations, including topical and systemic treatments, laser therapy, and emerging antifungal agents. Patient-Centric Care: Innovations focus on improving treatment efficacy, reducing treatment duration, and enhancing patient convenience and satisfaction. 💡 Market Dynamics: Growing Demand: The Dermatophytic Onychomycosis Treatment Market experiences steady growth due to the high prevalence of onychomycosis and the increasing demand for effective therapies. Technological Advancements: Ongoing research and development efforts drive technological advancements in treatment modalities, offering new options for patients and healthcare providers. #Company Bausch Health Companies Inc. Novartis Johnson & Johnson Galderma S.A. Celtic Pharmaceuticals Anacor Pharmaceuticals Moberg Pharma AB GSK Pfizer #Type • Systemic Therapy • Topical Therapy • Others #Application • Hospitals • Dermatology Clinics • Others #follow Stringent Datalytics - Healthcare #OnychomycosisTreatment #Dermatology #FungalInfections #HealthcareInnovation #PatientCare #LinkedInPost

DERMATOLOGY IN CLINICAL RESEARCH: A SOURCE OF NEW HOPE Did you know? Clinical research in dermatology is making a profound difference, offering breakthroughs for millions affected by skin diseases. With nearly 900 million people worldwide struggling with conditions like psoriasis, eczema, and acne, ongoing trials are delivering innovative treatments that promise better results. The rise of biologics, for example, has transformed care, providing targeted therapies that significantly improve patients' lives. Beyond physical relief, these advancements restore confidence and enhance quality of life. For those battling rare or severe skin disorders, dermatological research opens the door to long-term control, offering renewed hope. #DermatologyResearch #ClinicalTrials #SkinHealth #PsoriasisTreatment #EczemaCare #Biologics #InnovativeTherapies 

Repurposing of known medications beyond their original therapeutic indications is an increasingly attractive drug development path. Offering a cost-effective and time-efficient approach, this strategy is not a challenge-free process: issues related to intellectual property, drug formulation barriers or funding need to be surpassed. Successfully facing these challenges, BioResearch Pharma SA aims to provide new treatment options for dermatology patients. The company pipeline features drug repurposed candidates for psoriasis and androgenetic alopecia. Effective topical dermatology treatments can improve the quality of life for many patients. #pharma #dermatology 

We’re excited to announce that we’ve received a notice of claims allowance from the U.S. Patent and Trademark Office covering compositions and methods of use for the drug formulation of Zabalafin Hydrogel (AB-101a) for #atopicdermatitis. Zabalafin Hydrogel is our lead product candidate and is being developed as the first therapeutic for AD to directly treat AD’s itch, directly treat bacteria that are increasingly thought to cause AD’s inflammation and flares and cause infected AD skin, and directly treat AD’s inflammation. https://lnkd.in/guiFxDwf #dermatology #eczema #patents

🚀 FDA Approval Alert: Galderma's Nemluvio has been approved by the FDA as a treatment for a chronic skin condition, marking a significant advancement in dermatological care. 🌿 This new therapy is poised to offer much-needed relief to millions of patients, addressing a condition that has long been difficult to manage. This approval underscores the ongoing innovation in biopharma, bringing cutting-edge solutions to the market that can significantly enhance patient outcomes. 💼 🔗 Dive into the details of this breakthrough and its implications for patient care: https://lnkd.in/eGHCCZjb #FDAApproval #Dermatology #Biopharma #PatientCare #ChronicConditions

🌟 Introducing #DesmethylPimecrolimus Desmethyl Pimecrolimus CAS No: 1025113-89-6 CAT No-20126-01 🔬 Product Overview: Desmethyl Pimecrolimus is a novel compound developed by our team of experts to offer targeted therapy for various dermatological conditions, including eczema, psoriasis, and atopic dermatitis. With its unique mechanism of action, Desmethyl Pimecrolimus demonstrates promising efficacy in managing inflammation and providing long-lasting relief for patients suffering from these skin disorders. 💼 Connect with Us: www.prasilabs.com Learn more about Desmethyl Pimecrolimus and our other innovative products by visiting our website or contacting our team directly. Together, let's continue to drive progress in dermatology and redefine the standards of patient care. #PrasiLabs #DesmethylPimecrolimus #Dermatology #Innovation #Healthcare #Pharmaceuticals #DermatologicalResearch #Eczema #Psoriasis #AtopicDermatitis #MedicalAdvancement #PatientCare

Join Genemarkers’ Anna Langerveld and Jocelyn K. at the 8th Annual Dermatology Drug Development Summit on November 12-14, 2024 in Boston.  This is a great opportunity to learn how Genemarkers’ services can improve your drug development. To connect with Anna and Jocelyn during the event, email jkearsley@genemarkersllc.com or schedule a meeting directly: https://lnkd.in/ePKXEseV #Dermatology #Dermatologics  #DermatologyMedication #TopicalDermatology #DermatologyDrug #DrugDevelopment #Pharma #Pharmaceuticals #SkinScience #Skincare #DermalPharma #DermalResearch #DrugDiscovery #Preclinical #PreclinicalResearch #ClinicalTrial #ClinicalResearch